280 related articles for article (PubMed ID: 20144842)
1. Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Yigit R; Massuger LF; Figdor CG; Torensma R
Gynecol Oncol; 2010 May; 117(2):366-72. PubMed ID: 20144842
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer biology and immunotherapy.
Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
[TBL] [Abstract][Full Text] [Related]
3. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.
Chiriva-Internati M; Mirandola L; Kast WM; Jenkins MR; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):71-86. PubMed ID: 21557635
[TBL] [Abstract][Full Text] [Related]
4. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
Chiriva-Internati M; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
[TBL] [Abstract][Full Text] [Related]
5. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
6. Immunologic approaches to ovarian cancer treatment.
Sabbatini P; Odunsi K
J Clin Oncol; 2007 Jul; 25(20):2884-93. PubMed ID: 17617519
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
9. Host immune responses to cervical cancer.
Patel S; Chiplunkar S
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):54-9. PubMed ID: 19125004
[TBL] [Abstract][Full Text] [Related]
10. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
11. Immunopathogenesis of ovarian cancer.
Thompson MS; Mok SC
Minerva Med; 2009 Oct; 100(5):357-70. PubMed ID: 19910889
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer.
Ino K
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):13-8. PubMed ID: 20930628
[TBL] [Abstract][Full Text] [Related]
13. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
[TBL] [Abstract][Full Text] [Related]
14. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
Stewart TJ; Smyth MJ
Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
[TBL] [Abstract][Full Text] [Related]
15. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
16. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.
Cannon MJ; O'Brien TJ; Underwood LJ; Crew MD; Bondurant KL; Santin AD
Expert Rev Anticancer Ther; 2002 Feb; 2(1):97-105. PubMed ID: 12113075
[TBL] [Abstract][Full Text] [Related]
17. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.
Wei S; Kryczek I; Zou L; Daniel B; Cheng P; Mottram P; Curiel T; Lange A; Zou W
Cancer Res; 2005 Jun; 65(12):5020-6. PubMed ID: 15958543
[TBL] [Abstract][Full Text] [Related]
18. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
19. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
20. Tumor infiltrating lymphocytes in ovarian cancer.
Gasparri ML; Attar R; Palaia I; Perniola G; Marchetti C; Di Donato V; Farooqi AA; Papadia A; Panici PB
Asian Pac J Cancer Prev; 2015; 16(9):3635-8. PubMed ID: 25987014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]